Hikma Pharmaceuticals Plc Results of EGM (3042M)
May 20 2022 - 7:58AM
UK Regulatory
TIDMHIK
RNS Number : 3042M
Hikma Pharmaceuticals Plc
20 May 2022
Hikma Pharmaceuticals PLC
Results of 2022 Extraordinary General Meeting
LONDON, 20 May 2022 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ
Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its
Extraordinary General Meeting ("EGM"), held at 1 New Burlington
Place, W1S 2HR, London on 20 May 2022 commenced at 10:00 am. The
Proposed Special Resolution was passed.
Copies of the special resolution passed at the EGM have been
submitted to the FCA's Electronic Submission System and will be
available from the National Storage Mechanism.
The total number of votes cast on the poll for the resolution
(the full text of the resolution is detailed in the notice of the
EGM dated 25 April 2022) is set out below. The number of Ordinary
Shares in issue as at
20 May 2022 was 238,253,038. There were 12,833,233 Ordinary
Shares held in treasury, which are not counted in the voting
capital of the Company which, therefore, was 225,419,805.
Resolution Votes For % Votes % Total Cast Withheld
Against
1. Approve the Conversion
of the Merger Reserve
to a Distributable
Reserve 165,124,425 99.99 2,080 0.01 165,126,505 2,249
------------ ------ --------- ----- ------------ ---------
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMFBLFLLELEBBQ
(END) Dow Jones Newswires
May 20, 2022 07:58 ET (11:58 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2023 to Jun 2024